Logo Logo
Hilfe
Hilfe
Switch Language to English

Zheng, Lukai ORCID logoORCID: https://orcid.org/0000-0003-1328-2791; Rubinski, Anna; Denecke, Jannis ORCID logoORCID: https://orcid.org/0000-0003-4777-2238; Luan, Ying; Smith, Ruben; Strandberg, Olof; Stomrud, Erik; Ossenkoppele, Rik; Svaldi, Diana Otero; Higgins, Ixavier Alonzo; Shcherbinin, Sergey; Pontecorvo, Michael J.; Hansson, Oskar ORCID logoORCID: https://orcid.org/0000-0001-8467-7286; Franzmeier, Nicolai ORCID logoORCID: https://orcid.org/0000-0001-9736-2283 und Ewers, Michael ORCID logoORCID: https://orcid.org/0000-0001-5231-1714 (2023): Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease. In: Annals of Neurology [PDF, 2MB]

Abstract

Objective We aimed to test whether region-specific factors, including spatial expression patterns of the tau-encoding gene MAPT and regional levels of amyloid positron emission tomography (PET), enhance connectivity-based modeling of the spatial variability in tau-PET deposition in the Alzheimer disease (AD) spectrum.

Methods We included 685 participants (395 amyloid-positive participants within AD spectrum and 290 amyloid-negative controls) with tau-PET and amyloid-PET from 3 studies (Alzheimer's Disease Neuroimaging Initiative, 18F-AV-1451-A05, and BioFINDER-1). Resting-state functional magnetic resonance imaging was obtained in healthy controls (n = 1,000) from the Human Connectome Project, and MAPT gene expression from the Allen Human Brain Atlas. Based on a brain-parcellation atlas superimposed onto all modalities, we obtained region of interest (ROI)-to-ROI functional connectivity, ROI-level PET values, and MAPT gene expression. In stepwise regression analyses, we tested connectivity, MAPT gene expression, and amyloid-PET as predictors of group-averaged and individual tau-PET ROI values in amyloid-positive participants.

Results Connectivity alone explained 21.8 to 39.2% (range across 3 studies) of the variance in tau-PET ROI values averaged across amyloid-positive participants. Stepwise addition of MAPT gene expression and amyloid-PET increased the proportion of explained variance to 30.2 to 46.0% and 45.0 to 49.9%, respectively. Similarly, for the prediction of patient-level tau-PET ROI values, combining all 3 predictors significantly improved the variability explained (mean adjusted R2 range across studies = 0.118–0.148, 0.156–0.196, and 0.251–0.333 for connectivity alone, connectivity plus MAPT expression, and all 3 modalities combined, respectively).

Interpretation Across 3 study samples, combining the functional connectome and molecular properties substantially enhanced the explanatory power compared to single modalities, providing a valuable tool to explain regional susceptibility to tau deposition in AD. ANN NEUROL 2023

Dokument bearbeiten Dokument bearbeiten